Compare PHAR & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | SANA |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.4M | 793.1M |
| IPO Year | 2020 | 2021 |
| Metric | PHAR | SANA |
|---|---|---|
| Price | $9.95 | $2.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $34.35 | $8.43 |
| AVG Volume (30 Days) | 32.7K | ★ 3.4M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.92 | N/A |
| Revenue Next Year | $8.85 | N/A |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $2.61 |
| 52 Week High | $21.34 | $6.55 |
| Indicator | PHAR | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 36.78 |
| Support Level | $9.62 | $2.64 |
| Resistance Level | $11.60 | $3.41 |
| Average True Range (ATR) | 0.40 | 0.17 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 7.95 | 11.77 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.